Cerebral involvement in hypertensive cardiovascular disease

European Heart Journal, Supplement

Volumn 5, Issue F, 2003, Pages

  Coca, Antonio ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Angiotensin receptor blockers; Cognitive impairment; Dementia; Hypertension; Stroke; White matter lesions

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; TELMISARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRAIN INJURY; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; SYSTOLIC BLOOD PRESSURE; WHITE MATTER;

EID: 0041471398     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90012-5     Document Type: Conference Paper

References (27)

1. Kjeldsen SE, Julius S, Hedner T, et al. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press 2001;10:190-2.
2. Skoog I, Lernfelt B, Landaht S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5.
3. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990;82:1616-28.
4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-72.
5. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-64.
7. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
8. Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000;160:211-20.
9. Staessen JA, Wang JG, Thijs L, et al. Overview of the outcome trials in older patients with isolated systolic hypertension. J Hum Hypertens 1999;13:859-63.
10. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
11. Sierra C. Cerebral white matter lesions in essential hypertension. Curr Hypertens Rep 2001;3:429-33.
12. Sierra C, de La Sierra A, Mercader J, et al. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. J Hypertens 2002;20:519-24.
13. Liao D, Cooper L, Cai J, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke 1996;27:2262-70.
14. Breteler MM, van Swieten JC, Bots ML, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994;44:1246-52.
15. Kario K, Shimada K, Schwartz JE, et al. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol 2001;38:238-45.
16. Longstreth WT Jr, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996;27:1274-82.
17. Sierra C, de la Sierra A, Pare JC, et al. Correlation between silent cerebral white matter lesions and left ventricular mass and geometry in essential hypertension. Am J Hypertens 2002;15:507-12.
18. Derrer DS, Howieson DB, Mueller EA, et al. Memory testing in dementia: how much is enough? J Geriatr Psychiatry Neurol 2001;14:1-6.
19. Sierra C, de la Sierra A, Salamero M, et al. Silent cerebral white matter lesions and cognitive function in middle-aged essential hypertensive patients. Hypertension 2002;40:423.
20. Di Bari M, Pahor M, Franse LV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol 2001;153:72-8.
21. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
22. Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide on dementia and cognitive decline in patients with cardiovascular disease. Arch Intern Med 2003;163:1069-75.
23. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
24. Lithell H, Hansson L, Skoog I, et al. The Study of Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86.
25. Culman J, Blume A, Gohlke P, et al. The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers. J Hum Hypertens 2002;16(suppl 3):S64-70.
26. Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8.
27. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002;20:71-8.